

Federico Pozzo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3825780/publications.pdf>

Version: 2024-02-01

40
papers

565
citations

623734

14
h-index

642732

23
g-index

40
all docs

40
docs citations

40
times ranked

969
citing authors

#	ARTICLE	IF	CITATIONS
1	Elastin Microfibril Interfacer1 (EMILIN1) is an alternative prosurvival VLA4 ligand in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2022, 40, 181-190.	1.7	3
2	KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders. <i>Cancers</i> , 2022, 14, 666.	3.7	8
3	Multiple Mechanisms of NOTCH1 Activation in Chronic Lymphocytic Leukemia: NOTCH1 Mutations and Beyond. <i>Cancers</i> , 2022, 14, 2997.	3.7	5
4	Integrin Signaling Shaping BTK-Inhibitor Resistance. <i>Cells</i> , 2022, 11, 2235.	4.1	3
5	Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia. <i>Haematologica</i> , 2021, 106, 2345-2353.	3.5	8
6	TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 5566-5575.	7.0	23
7	COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients. <i>Hematological Oncology</i> , 2021, 39, 712-714.	1.7	17
8	SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation. <i>Haematologica</i> , 2021, 106, 3125-3135.	3.5	12
9	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. <i>Blood</i> , 2020, 135, 1244-1254.	1.4	33
10	An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy. <i>Cancers</i> , 2020, 12, 894.	3.7	22
11	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. <i>Leukemia</i> , 2019, 33, 2111-2115.	7.2	21
12	Clinical Impact of Clonal and Subclonal TP53 Mutations and Deletions in Chronic Lymphocytic Leukemia: An Italian Multicenter Experience. <i>Blood</i> , 2019, 134, 480-480.	1.4	12
13	Impaired Nodal Shrinkage and Apoptosis Lacking Define the Adverse Independent Clinical Outcome of NOTCH1 mutated Chronic Lymphocytic Leukemia (CLL) Patients in the Age of Targeted Agents (TA). <i>Blood</i> , 2019, 134, 1744-1744.	1.4	0
14	NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. <i>British Journal of Haematology</i> , 2018, 182, 597-602.	2.5	22
15	NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF- κ B pathways. <i>Leukemia</i> , 2018, 32, 654-662.	7.2	31
16	Clinical Relevance of NOTCH1 Mutations in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 4396-4396.	1.4	2
17	The Amount of Apoptosis Predicts Outcome in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 4397-4397.	1.4	3
18	Intraclonal Diversification Occurs in Chronic Lymphocytic Leukemia Expressing B Cell Receptors Belonging to the IGHV4 Gene Family. <i>Blood</i> , 2018, 132, 944-944.	1.4	0

#	ARTICLE	IF	CITATIONS
19	SF3B1 Mutations Associate with Low CD20 Expression in CLL: Another NOTCH1-Dependent Mechanism?. Blood, 2018, 132, 1838-1838.	1.4	0
20	Clinical Impact of Clonal and Subclonal TP53 Mutations in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 945-945.	1.4	0
21	KRAS, NRAS and BRAF Mutations Are Highly Enriched in TR12 Chronic Lymphocytic Leukemia and Are Associated to Shorter Time to First Treatment. Blood, 2018, 132, 3113-3113.	1.4	0
22	Mutations in the 3' untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia. Haematologica, 2017, 102, e305-e309.	3.5	18
23	NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. Leukemia, 2017, 31, 2407-2415.	7.2	52
24	Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. Haematologica, 2017, 102, e443-e446.	3.5	11
25	CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. Leukemia, 2016, 30, 2011-2018.	7.2	41
26	NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. Leukemia, 2016, 30, 182-189.	7.2	74
27	Mutations at 3' Untranslated Region (3'UTR) of NOTCH1 Are Associated with Low CD20 Expression Levels in Chronic Lymphocytic Leukemia. Blood, 2016, 128, 306-306.	1.4	0
28	Lack of Prognostic Significance of the Conventional and Novel Prognostic Markers in Trisomy 12 Chronic Lymphocytic Leukemia (CLL). Blood, 2016, 128, 4354-4354.	1.4	0
29	Comprehensive Characterization of NOTCH1 Mutational Status in Chronic Lymphocytic Leukemia: Clinical Relevance of Subclonal Mutations and Mutation Types. Blood, 2016, 128, 3195-3195.	1.4	0
30	Apoptosis and Proliferation Synergistically Determine Overall Survival in Chronic Lymphocytic Leukemia (CLL). Blood, 2015, 126, 1718-1718.	1.4	0
31	CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34+ hemopoietic progenitors cells. Leukemia, 2014, 28, 705-708.	7.2	10
32	NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. Annals of Hematology, 2014, 93, 1765-1774.	1.8	34
33	NOTCH1 Mutations Are Associated with Low CD20 Expression in Chronic Lymphocytic Leukemia: Evidences for a NOTCH1-Mediated Epigenetic Regulatory Mechanism. Blood, 2014, 124, 296-296.	1.4	5
34	NOTCH1 Mutations Are Associated with High CD49d Expression in Chronic Lymphocytic Leukemia. Blood, 2014, 124, 1978-1978.	1.4	0
35	Clinical significance of 7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia. British Journal of Haematology, 2013, 160, 415-418.	2.5	14
36	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. Journal of Hematology and Oncology, 2013, 6, 83.	17.0	14

#	ARTICLE	IF	CITATIONS
37	<i>ARHGDI3</i> , a mutant <i>TP53</i> -associated Rho GTPase dissociation inhibitor, is overexpressed in gene expression profiles of <i>TP53</i> disrupted chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2013, 161, 596-599.	2.5	3
38	CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. <i>Blood</i> , 2013, 122, 3317-3321.	1.4	48
39	Clinical Significance of NOTCH1 mutations in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2012, 120, 2870-2870.	1.4	0
40	A Simple Multiplex Real-Time PCR Methodology for the SMN1 Gene Copy Number Quantification. <i>Genetic Testing and Molecular Biomarkers</i> , 2009, 13, 37-42.	0.7	16